Urinary metabolomics (GC-MS) reveals that low and high birth weight infants share elevated inositol concentrations at birth

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 27, Issue , 2014, Pages 20-26

  Barberini, Luigi ^a   Noto, Antonio ^b   Fattuoni, Claudia ^a   Grapov, Dmitry ^c   Casanova, Andrea ^a   Fenu, Gianni ^a   Gaviano, Mauro ^a   Carboni, Roberta ^b   Ottonello, Giovanni ^b   Crisafulli, Maurizio ^b   Fanos, Vassilios ^b   Dessì, Angelica ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b DEPARTMENT OF RADIOLOGY   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

GC MS; Inositol; IUGR; Metabolomics; OSC PLS DA

Indexed keywords

INOSITOL; BIOLOGICAL MARKER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH BIRTH WEIGHT; HUMAN; INTRAUTERINE GROWTH RETARDATION; LARGE FOR GESTATIONAL AGE; LOW BIRTH WEIGHT; MALE; MASS FRAGMENTOGRAPHY; METABOLOMICS; MULTIVARIATE ANALYSIS; NEWBORN; PARTIAL LEAST SQUARES DISCRIMINANT ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; URINALYSIS; BIRTH WEIGHT; GESTATIONAL AGE; ITALY; METABOLIC SYNDROME X; METABOLISM; NEWBORN DISEASE; PROCEDURES; URINE;

BIOLOGICAL MARKERS; BIRTH WEIGHT; FEMALE; FETAL GROWTH RETARDATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INOSITOL; ITALY; MALE; METABOLIC SYNDROME X; METABOLOMICS; ROC CURVE;

EID: 84911870527     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2014.954786     Document Type: Article

References (26)

1. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying 4 drug toxicity and gene function. Nat Rev Drug Discov 2002;1:153-61.
2. Dessì A, Fanos V. Pediatric obesity: could metabolomics be a useful tool? J Pediat Neonatal Individualized Med 2013;2: e020205.
3. Dessì A, Puddu M, Ottonello G, Fanos V. Metabolomics and fetal-neonatal nutrition: between "not enough" and "too much." Molecules 2013;18:11724-32.
4. Committee on Practice Bulletins-Gynecology, American College of Obstetricians and Gynecologists, Washington, DC 20090-6920, USA. Intrauterine growth restriction. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2001;72: 85-96.
5. nd ed. Umeà, Sweden: Umetrics AB.
6. Wehrens R, Carvalho E, Masuero D, et al. High-throughput carotenoid profiling using multivariate curve resolution. Anal Bioanal Chem 2013;405:5075-86.
7. Svensson O, Kourti T, MacGregor JF. An investigation of orthogonal signal correction algorithms and their characteristics. J Chemometr 2002;16:176-88.
8. Smilowitz JT, Totten SM, Huang J, et al. Human milk secretory immunoglobulin A and lactoferrin N-glycans are altered in women with gestational diabetes mellitus. J Nutr 2013;143: 1906-12.
9. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013;9:280-99.
10. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013. Available from: http://www.R-project.org/[last accessed 8 Feb 2014].
11. Wehrens R. Orthogonal signal correction and OPLS. In: Gentleman R, Hornik K, Parmigiani G, editors. Chemometrics. Berlin, Heidelberg: Springer-Verlag; 2011:240-3.
12. Dessì A, Fanos V. Myoinositol: a new marker of intrauterine growth restriction? J Obstet Gynaecol 2013;33:776-80.
13. Kennington AS, Hill CR, Craig J, et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. New Engl J Med 1990;323:373-8.
14. Ostlund Jr RE, McGill JB, Herskowitz I, et al. D-chiro-inositol metabolism in diabetes mellitus. Proc Natl Acad Sci USA 1993;90: 9988-92.
15. Downes CP, Macphee CH. Myo-inositol metabolites as cellular signals. Eur J Biochem 1990;193:1-18.
16. Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 2013;95:1811-27.
17. Sun TH, Heimark DB, Nguygen T, et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Bioph Res Co 2002;293: 1092-8.
18. Asplin I, Galasko G, Larner J. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol-and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 1993;90:5924-8.
19. Harder T, Rodekamp E, Schellong K, et al. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol 2007;165:849-57.
20. Barker DJ, Osmond C. Infant mortality, childhood nutrition and ischaemic heart disease in England and Wales. Lancet 1986;1: 1077-81.
21. Puddu M, Fanos V, Podda F, Zaffanello M. The kidney from prenatal to adult life: perinatal programming and reduction of number of nephrons during development. Am J Nephrol 2009;30: 162-70.
22. Holemans K, Aerts L, Van Assche FA. Lifetime consequences of abnormal fetal pancreatic development. J Physiol 2003;547: 11-20.
23. Fernandez-Twinn DS, Ozanne SE. Mechanisms by which poor early growth programs type-2 diabetes, obesity and the metabolic syndrome. Physiol Behav 2006;88:234-3.
24. Lam YY, Hatzinikolas G, Weir JM, et al. Insulin-stimulated glucose uptake and pathways regulating energy metabolism in skeletal muscle cells: the effects of subcutaneous and visceral fat, and long-chain saturated, n-3 and n-6 polyunsaturated fatty acids. Biochim Biophys Acta 2011;1811:468-575.
25. Nissen PM, Nebel C, Oksbjerg N, Bertram HC. Metabolomics reveals relationship between plasma inositols and birth weight: possible markers for fetal programming of type 2 diabetes. J Biomed Biotechnol 2011. 2011: Article ID 378268.
26. Dessì A, Atzori L, Noto A, et al. Metabolomics in newborns with intrauterine growth retardation (IUGR): urine reveals markers of metabolic syndrome. J Matern-Fetal Neo M 2011;24: 35-9.